Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash from Financing Activities: 2016-2025

Historic Cash from Financing Activities for Summit Therapeutics (SMMT) over the last 7 years, with Sep 2025 value amounting to $33.8 million.

  • Summit Therapeutics' Cash from Financing Activities fell 83.44% to $33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year decrease of 95.11%. This contributed to the annual value of $381.2 million for FY2024, which is 340.66% up from last year.
  • Summit Therapeutics' Cash from Financing Activities amounted to $33.8 million in Q3 2025, which was up 1,421.74% from $2.2 million recorded in Q2 2025.
  • Summit Therapeutics' Cash from Financing Activities' 5-year high stood at $520.1 million during Q4 2022, with a 5-year trough of -$23.6 million in Q4 2024.
  • Its 3-year average for Cash from Financing Activities is $46.5 million, with a median of $6.3 million in 2023.
  • As far as peak fluctuations go, Summit Therapeutics' Cash from Financing Activities surged by 1,863,133.33% in 2021, and later slumped by 477.67% in 2024.
  • Summit Therapeutics' Cash from Financing Activities (Quarterly) stood at $1.3 million in 2021, then surged by 41,141.87% to $520.1 million in 2022, then plummeted by 98.80% to $6.3 million in 2023, then plummeted by 477.67% to -$23.6 million in 2024, then plummeted by 83.44% to $33.8 million in 2025.
  • Its Cash from Financing Activities was $33.8 million in Q3 2025, compared to $2.2 million in Q2 2025 and $7.7 million in Q1 2025.